By Dr. Liji Thomas, MD Reviewed by Benedette Cuffari, M.Sc. Sep 16 2024 Emerging evidence reveals that COVID-19 antiviral therapies may pose severe cardiovascular risks, urging caution in treating vulnerable patients. Study:  Cardiovascular adverse effects of antiviral therapies for COVID-19: Evidence and plausible mechanisms.  Image Credit: Corona Borealis Studio / Shutterstock.com Several antivirals, including remdesivir, Paxlovid, molnupiravir, and monoclonal antibodies like tixagevimab and

Tag-uri: Coronavirus